You are here

Takeda

ASH: Takeda details Ninlaro's miss in scrapped AL amyloidosis trial

ASH: Takeda details Ninlaro's miss in scrapped AL amyloidosis trial

Fierce Pharma

Flag link:

Takeda's dengue vaccine efficacy slips between 12- and 18-month analyses

Takeda's dengue vaccine efficacy slips between 12- and 18-month analyses

Fierce Pharma

Flag link:

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Pharmaforum

clinical trials

ALK-positive non-small cell lung cancer

Flag link:

Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Fierce Pharma

ALK-positive non-small cell lung cancer

Flag link:

Takeda sees cell, gene therapy in its future. Is it too late?

Takeda sees cell, gene therapy in its future. Is it too late?

Biopharma Dive

Flag link:

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease

Endpoints

Finch Therapeutics

Crohn's Disease

Flag link:

Orphan Drug Recall Leaves Patients in the Lurch

Orphan Drug Recall Leaves Patients in the Lurch

RAPS.org

hypoparathyroidism

product recalls

Flag link:

Takeda scores a win for Ninlaro as it aims to pioneer 'switch' maintenance in multiple myeloma

Takeda scores a win for Ninlaro as it aims to pioneer 'switch' maintenance in multiple myeloma

Fierce Pharma

Multiple Myeloma

clinical trials

Flag link:

Early data on Takeda's dengue vaccine is promising, but wait for the full dataset

Early data on Takeda's dengue vaccine is promising, but wait for the full dataset

Endpoints

clinical trials

Flag link:

Takeda's dengue shot 80% effective in massive phase 3 test

Takeda's dengue shot 80% effective in massive phase 3 test

Fierce Pharma

clinical trials

Flag link:

Takeda nets $660m from product selloff to Germany’s Stada

Takeda nets $660m from product selloff to Germany’s Stada

Pharmaforum

Flag link:

Takeda acquires TAK-101 license from COUR in $420m deal

Takeda acquires TAK-101 license from COUR in $420m deal

Pharmaceutical Business Review

COUR Pharmaceutical Development

Flag link:

Takeda pares down products and jobs, revives Genzyme building plans

Takeda pares down products and jobs, revives Genzyme building plans

Bizjournals

Flag link:

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

Pharmaforum

Flag link:

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

Pharmaforum

Flag link:

Takeda breaks into top 20 largest pharmas with Shire merger

Takeda breaks into top 20 largest pharmas with Shire merger

Pharmaforum

Flag link:

Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

Pharmaceutical Business Review

CB1 monoclonal antibodies

Flag link:

Takeda pens Prometheus pact to find novel IBD targets

Takeda pens Prometheus pact to find novel IBD targets

Fierce Biotech

inflammatory bowel disease

Promethera Biosciences

Flag link:

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Fierce Pharma

Flag link:

Takeda eyes emerging markets asset sale to trim its debt; report

Takeda eyes emerging markets asset sale to trim its debt; report

Pharmaforum

emerging markets

Flag link:

Pages